Physician profile
Joshua E Bernstein
NPI 1609882059
$4,571.67
in general payments reported to CMS, 2019-2025
40 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $120 · 2021: $101 · 2022: $273 · 2023: $808 · 2024: $1,129 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094 · Education: $29.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.08 |
| Education | $29.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $702.03 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $678.75 | 2019-2025 | Breztri, Nexium, Airsupra |
| Lilly USA, LLC | $547.62 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $431.82 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $348.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $280.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $219.94 | 2022-2025 | |
| Amgen INC. | $201.74 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $118.76 | 2019-2024 | Octrode, Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $103.51 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.14 | 2019-2024 | Xifaxan |
| Cranial Technologies, INC | $88.36 | 2021-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $81.92 | 2019-2025 | Enflonsia, Capvaxive |
| Sanofi Pasteur INC. | $55.95 | 2019-2025 | |
| Exact Sciences Corporation | $46.34 | 2025 | The Cologuard Plus Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.